An actual paradigm for activation and regulation of the GPCR (G-protein-coupled receptors)/seven-transmembrane helix family of receptors essentially emerges from extensive studies of the largest family of receptors, the GPCR-A/rhodopsin family. The mechanisms regulating the GPCR-B family signal transduction are less precisely understood due in part to the lack of the conserved signatures of the GPCR-A family (E/DRY, NPXXY) and in part to the absence of a reliable receptor modelling, although some studies suggest that both families share similar features. Here, we try to highlight the current knowledge of the activation and the regulation of the VIP (vasoactive intestinal peptide) receptors, namely VPAC (VIP/pituitary adenylate cyclase-activating peptide receptor) 1 and 2. This includes search for amino acids involved in the stabilization of the receptor active conformation and in coupling to G-proteins, signalling pathways activated in response to VIP, agonist-dependent receptor down-regulation, phosphorylation and internalization as well as pharmacological consequences of receptor hetero-dimerization.
Introduction
GPCRs (G-protein-coupled receptors) constitute a large family sharing a common membrane topology with an extracellular N-terminus, a cytoplasmic C-terminus and seven TM (transmembrane) domains connected by loops. This family includes receptors for endogenous ligands such as hormones, neurotransmitters, neuromodulators and chemokines with a large diversity of chemical structures such as amine, amino acids, peptides, nucleosides, nucleotides, glycoproteins, phospholipids, fatty acids and also sensory receptors for exogenous ligands such as odorants, tastants, pheromones and photons. GPCRs mediate most of their intracellular actions through pathways involving G-protein activation that transmit the signal to effector proteins through rapid changes in the concentration of intracellular signalling molecules [1] .
The GPCR-B family contains 25 members including the receptors for glucagon, secretin, VIP (vasoactive intestinal peptide), PACAP (pituitary adenylate cyclase-activating polypeptide), GLP (glucagon-like-peptide) 1 and 2, calcitoKey words: dimerization, G-protein-coupled receptor (GPCR), internalization, phosphorylation, signalling, vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor (VPAC). Abbreviations used: ERK, extracellular-signal-regulated kinase; GLP, glucagon-like-peptide; GPCR, G-protein-coupled receptors; GRK, GPCR kinase; IC, intracellular loop; MAPK, mitogenactivated protein kinase; PI3K, phosphatidylinositol 3-kinase; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C; PLD, phospholipase D; PTx, pertussis toxin; TM, transmembrane; VIP, vasoactive intestinal peptide; VPAC, VIP/pituitary adenylate cyclase-activating peptide receptor. 1 To whom correspondence should be addressed (email ilanger@ulb.ac.be).
nin, parathyroid hormone, growth-hormone-releasing hormone, and corticotropin-releasing factor. Adenylate cyclase activation through coupling to Gα s is the main signalling pathway of these receptors although a coupling to the PLC (phospholipase C) and the calcium/InsP 3 pathway through either Gα q or Gα i is also effective [1] . Here, we try to highlight the current knowledge of the activation and the regulation of the VIP receptors, namely VPAC (VIP/pituitary adenylate cyclase-activating peptide receptor) 1 ( Figure 1 ) and 2, and fit it into the current view that emerges from studies of the largest family of receptors, the GPCR-A/rhodopsin family.
Receptor activation
Upon ligand binding, which involves a hydrophobic core made of TM helices (small ligands) and/or N-terminus and extracellular loops (peptides and proteins), GPCRs undergo physical/conformational changes that allow interaction of cytoplasmic domains with heterotrimeric G-proteins and promote exchange of GDP for GTP on the Gα subunit. This initiates the dissociation of the GTP-bound Gα subunit from the Gβγ dimer and activation of downstream effector pathways. Signals are terminated following hydrolysis of Gα-bound GTP and reformation of inactive trimeric complex [1] . For the GPCR-A family, key steps frequently involved in the early signalling events include: (i) protonation of the acidic residue of the highly conserved E/DRY (Glu/Asp-Arg-Tyr) motif located at junction of TM3 and IC (intracellular loop) 2, (ii) disruption of a network of interactions between TM (mainly TM3, TM6 and TM7) maintaining the receptor preferentially in a ground inactive conformation in the absence of agonist, and (iii) movements of TM3 and TM6 causing key sequences to be exposed to cytoplasmic binding partners [2, 3] . As do all members of GPCR-B family, VIP receptors lack the E/DRY sequence. On the basis of subtle changes observed when Tyr 239 and Leu 240 in VPAC1, which are highly conserved in the GPCR-B family and located at the same position than the E/DRY sequence of the GPCR-A family, were replaced by alanine, it was proposed that this YL (TyrLeu) sequence was equivalent to the E/DRY motif of GPCR-A family and involved in G-protein binding [4] . Our results do not support the conclusions of this study [5] . One possible explanation for the discrepancy can be the fact that Tams et al. [4] studied cyclic AMP measurements in intact cells, a more sensitive model than the adenylate cyclase assay on membrane used in our study. Nevertheless, even if the YL motif of GPCR-B family and the E/DRY motif of GPCR-A family have the same location, they certainly do not have the same importance for receptor activation. Another model based on a three-dimensional analysis of the GLP-1 receptor proposed that a E/DRY motif could be formed by three non-adjacent residues consisting of Arg 174 in the cytoplasmic end of TM2, Glu 236 and Tyr 239 in the distal part of TM3 of VPAC1 [6] , but in our hands E236A and Y239A [5] and R174A mutants (I. Nachtergael, P. Robberecht and I. Langer, unpublished work) were undistinguishable from the wild-type receptor.
Similarly, a precise network of interaction between TMs was not yet proposed for the GPCR-B family. Actually, a larger network must be considered for VIP receptors according to mutagenesis studies that suggest the participation of TM1 (Tyr  146 and Tyr  150 in VPAC1 and Tyr  130 and Tyr 134 in VPAC2) [7] , TM2 (Lys 195 in VPAC1 and Lys 179 in VPAC2) [8, 9] , TM3 (Asn 229 in VPAC1 and Asn 216 in VPAC2) [5, 4] and TM6 (Thr 343 in VPAC1) [10] in receptor activation.
G-protein-receptor interactions
The α subunit of heterotrimeric G-proteins has a central role in interaction with both the receptor and the effectors. Several studies have shown that the C-terminal part of the Gα subunit can directly bind to the receptor and is involved in the coupling specificity [11] . At the receptor level, the study of chimaeric or mutated seven-TM receptors demonstrated that the IC2 and IC3 and, to a lesser extent, the proximal part of the C-terminal tail (C) can be directly involved in G-proteinreceptor interaction. These observations are in good agreement with the current model of receptor activation: when the receptor switches to its active conformation, TM movements are accompanied by IC2 and IC3 movements leading to exposure of the G-protein-binding pocket to cytosol and G-protein-receptor interaction [3] . However, the diversity of sequences and loop sizes as well as their flexibility have made the identification of a specific set of residues difficult in defining the coupling profile. For VIP receptors, Gα-binding domains are mainly located in the IC3 that contains subdomains dedicated to the recognition of the different Gα subunits. In VPAC1, Lys 322 located in IC3 and Glu 394 located in proximal C-terminal tail are required for adenylate cyclase activation and coupling to Gα s [12, 13] , the distal part of IC3 [RLAR (Arg-Leu-Ala-Arg) sequence] is necessary for the triggering of VIP-stimulated calcium increase through Gα i [13] and the middle part of IC3 [IRKS (Ile-Arg-Lys-Ser) sequence] is involved in efficient coupling of VPAC1 to Gα i/o and Gα q [14] . In VPAC2, Leu 310 located in the proximal part of IC3 contributes to Gα s activation and the proximal part of IC3 (Arg   325 and Lys 328 ) is involved in both Gα s and Gα 16 coupling [15] . Among the different members of the GPCR-B family, proximal and distal domains of IC3 share conserved sequences that could therefore represent common G-protein-binding motifs. In line with this hypothesis, studies performed on other members of the GPCR-B family identified the proximal domain of IC3 as essential for adenylate cyclase activation, but the amino acids involved may differ, and additional conserved sequences located in other intracellular regions of the receptor may also be necessary as seen for glucagon (IC2) [16] , VPAC1 (Glu 394 located in C-terminus) [12] and CGRP1 (calcitonin gene-related peptide 1) receptors (Arg 151 located in IC1) [17] .
Signalling pathways
As mentioned above, in addition to Gα s coupling leading to the activation of adenylate cyclase and subsequent cAMP production, VIP receptors are also able to activate PLC in a partly PTx (pertussis toxin)-sensitive manner [18, 14] . However, PTx-sensitive mechanisms leading to PLC activation are different for VPAC1 and VPAC2. Cross-linking studies demonstrated a physical interaction between VPAC1 and Gα i and VPAC1-induced [Ca 2+ ] i increase is not affected by chelating of extracellular Ca 2+ [14] , while PTx-sensitive activation of PLC by VPAC2 relies on the availability of free Gβγ and on Ca 2+ entry through receptor-operated Ca 2+ channels [19] . Accumulation of intracellular cAMP also leads activation of PKA (protein kinase A) that may activate the ERK (extracellular-signal-regulated kinase) signalling pathway to promote pituitary cells proliferation [20] and neuroendocrine differentiation in prostate cancer cell line [21] . VIP-induced PKA activation is also responsible for most of the anti-inflammatory activity of VIP by regulating several signalling pathways and transcription factors thus increasing anti-inflammatory cytokine and reducing pro-inflammatory cytokines [22] . These include inhibition of STAT1 (signal transducer and activator of transcription 1) and MEKK1 [MAPK (mitogen-activated protein kinase)/ERK kinase kinase 1] phosphorylation, inhibition of NF-κB (nuclear factor κB), phosphorylation of CREB (cAMP-response-elementbinding protein) and up-regulation of JunB synthesis [22] . Additional coupling events that are not G-protein-mediated may also elicit auxiliary signals. Both VPAC1 and VPAC2 are able to activate PLD (phospholipase D). PLD responses induced by VPAC2 are not affected by PLC inhibitors, PTx or PKA inhibitors, but are sensitive to brefeldin A, which is an inhibitor of ARF (ADP-ribosylation factor) known to act as a direct activator of PLD [23] . In pancreatic β-cells, VIP-induced-sustained stimulation of insulin secretion is mediated by PI3K (phosphatidylinositol 3-kinase) activation by VPAC2 [24] . In the rat pineal gland, VIP stimulates cGMP formation through activation of nitric oxide synthase, nitric oxide (NO) production and activation of cytosolic guanylate cyclase [25] .
Receptor regulation
Beside G-protein coupling, GPCR activation by agonists also initiates the process of receptor desensitization, an adaptive response contributing to rapidly fade the G-protein signalling. This process starts with phosphorylation of the receptors in intracellular loops and C-terminus by activity-dependent kinases [PKA and PKC (protein kinase C)] and/or by receptor-activated-dependent kinases (GPCR kinases or GRKs). GRK-mediated phosphorylation of the receptor promotes the high-affinity binding of β-arrestins to the receptor, which both sterically prevents further coupling of G-protein and may act as a signal transducer to activate, for instance, MAPKs, Akt and PI3Ks [26] . β-Arrestins are also able to bind proteins of the endocytic machinery including clathrin and AP2 (adaptor protein 2) and promote receptor internalization [26] . GPCRs can be divided into two broad classes based on differences in their apparent affinities for β-arrestins and on their ability to maintain a scaffold with β-arrestin after internalization. After agonist stimulation, the first class of receptors (exemplified by the β 2 -adrenergic receptor) presents low affinity for β-arrestin, and the unstable complex dissociates at or near the membrane shortly after the formation of the coated pits, excluding the β-arrestin from the endocytic vesicles. By contrast, the second class of GPCR (exemplified by the vasopressin V 2 receptor) is characterized by a stable complex with β-arrestin that remains intact after internalization. Subsequently, in the first situation, the receptor is rapidly recycled back to the membrane, whereas, in the second case, the receptor, still associated with β-arrestin, is constrained within the endosomes and recycles slowly or is degraded in lysosomes [26] . Like most GPCRs, VPAC1 and VPAC2 are rapidly phosphorylated after agonist exposure. The absence of inhibitory effect of PKA and PKC inhibitors [15, 27] and the use of dominant-negative GRK and GRK overexpression experiments [28, 29] , suggest that GRKs are the main kinases involved in VIP receptor phosphorylation. By using sitedirected mutagenesis studies, we identified [30] . Combining the mutations of these identified residues indicated that the effect on phosphorylation was not additive, and the mutants tested maintained a phosphorylation level of approx. 30% of that observed for the wild-type receptor except when all the serine/threonine residues of the Cterminus were mutated [27] . We were unable to establish a direct correlation between the VPAC1 phosphorylation level and internalization, as, in some mutated receptors, a 70% reduction in phosphorylation has no or little effect on receptor internalization and only mutation of all the serine/threonine residues of the C-terminus completely abolished VPAC1 internalization [27] . VPAC1 and VPAC2 are both rapidly internalized following agonist exposure, but differ in their trafficking pattern. After internalization, VPAC1 is not reexpressed at the cell surface within 2 h of agonist washing, while VPAC2 is recycled back to the cell surface [27, 31] . In VPAC2, we found that G-protein coupling-inactivating mutations reduced both receptor phosphorylation and internalization in a manner that appeared to be linked directly to the alteration of the Gα s and Gα 16 coupling [15] . As mutants studied do not affect phosphorylatable residues, this suggests that impaired receptor phosphorylation and internalization directly reflect the reduced ability of the mutants to adopt active receptor conformation. However, we found that VIPstimulated phosphorylation of N229A and N229Q VPAC1 (two mutants characterized by a decrease in potency and efficacy of VIP-stimulated adenylate cyclase activity, by the absence of agonist-stimulated [Ca 2+ ] i increase, by a preserved receptor recognition of agonists and antagonist and by a preserved sensitivity to GTP) was only slightly decreased, that receptor internalization was comparable with that of the wild-type receptor, but that both N229A and N229Q mutants were rapidly re-expressed at the cell surface upon VIP washing [5] . As Asn 229 is located in the middle of TM3, it seems unlikely that it could be in direct interaction with β-arrestin, but probably contributes to receptor conformation necessary for high-affinity binding with β-arrestin. This latter study thus suggests that receptor conformation necessary for activation and regulatory mechanisms could be different.
Receptor dimerization
The classical model of ligand binding, GPCR activation and signal transduction is based on the concept that GPCRs exist and function as individual entities. However, studies have demonstrated that the pharmacological behaviour of GPCRs may be modified by the presence of other, structurally related or not, receptors. Besides the recognized post-receptor interactions, recent biochemical and biophysical studies indicate that, as for single transmembrane receptors, GPCRs are also able to form oligomeric complexes either with themselves (homo-oligomerization) or with other receptors (heterooligomerization) that may eventually affect the pharmacological profile and the signalling pathways [32] . Harikumar et al. [33] demonstrated, by using biophysical methods, that VPAC1 and VPAC2 formed constitutive homo-and heterodimers, and we studied the pharmacological properties of VPAC1 and VPAC2 co-expressed in CHO (Chinese-hamster ovary) cells [34] . We confirmed by co-immunoprecipitation that the two receptors did interact and found that receptor coexpression did not modify VIP or selective agonist affinities. Similarly, the potency of agonists to stimulate adenylate cyclase activity was unaffected, suggesting that the properties of the selective ligands that were established on cell lines expressing a single population of VIP receptors were valid on cells expressing both receptors. Similarly, VIP receptor co-expression did not modify receptor internalization and trafficking patterns following VIP or selective agonist exposure [34] . Besides pharmacological and functional regulation, it was also demonstrated that GPCR oligomerization plays a role in receptor maturation and cell-surface expression. The apparent lack of pharmacological consequences of VPAC1 and VPAC2 co-expression suggests that VIP receptor oligomerization modulates receptor expression rather than activity.
